Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  1998-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/JCEM.83.3.4641PMID 9506734
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide

  2006cited by this paper
• Erratum to: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients

  1996cited by this paper
• Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus.

  1996cited by this paper
• Proinsulin, C-peptide, and insulin in normal subjects during an 8-h hyperglycemic clamp.

  1996cited by this paper
• The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

  1996cited by this paper
• Effect of Troglitazone on Insulin Sensitivity and Pancreatic β-Cell Function in Women at High Risk for NIDDM

  1996cited by this paper
• The effect of insulin dose on the measurement of insulin sensitivity by the minimal model technique. Evidence for saturable insulin transport in humans.

  1996cited by this paper
• Hyperproinsulinemia in the diabetic Psammomys obesus is a result of increased secretory demand on the beta-cell.

  1995cited by this paper
• Metabolic effects of troglitazone on fat-induced insulin resistance in the rat.

  1995cited by this paper
• Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents.

  1995cited by this paper
• Increased secretory demand rather than a defect in the proinsulin conversion mechanism causes hyperproinsulinemia in a glucose-infusion rat model of non-insulin-dependent diabetes mellitus.

  1995cited by this paper
• Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity--clinical research center study.

  1995cited by this paper
• Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats.

  1995cited by this paper
• Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

  1994cited by this paper
• The Contribution of Insulin-Dependent and Insulin-Independent Glucose Uptake to Intravenous Glucose Tolerance in Healthy Human Subjects

  1994cited by this paper
• Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus.

  1992cited by this paper
• Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects

  1992cited by this paper
• β-cells in type II diabetes mellitus

  1991cited by this paper
• Banting lecture 1990. Beta-cells in type II diabetes mellitus.

  1991cited by this paper
• Prolonged Maximal Stimulation of Insulin Secretion in Healthy Subjects Does Not Provoke Preferential Release of Proinsulin

  1991cited by this paper
• Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice.

  1991cited by this paper
• Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM

  1991cited by this paper
• Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects.

  1990cited by this paper
• Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus.

  1990cited by this paper
• Effect of exercise on insulin action, glucose tolerance, and insulin secretion in aging.

  1990cited by this paper
• Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose.

  1990cited by this paper
• Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance.

  1989cited by this paper
• Increased β-Cell Secretory Capacity as Mechanism for Islet Adaptation to Nicotinic Acid-Induced Insulin Resistance

  1989cited by this paper
• Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats

  1988cited by this paper
• Disproportionate elevation of immunoreactive proinsulin in Type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance

  1987cited by this paper
• A sensitive radioimmunoassay for human proinsulin, with sequential use of antisera to C-peptide and insulin.

  1986cited by this paper
• Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.

  1984cited by this paper
• Quantitative estimation of insulin sensitivity.

  1979cited by this paper
• Circulating proinsulin in patients with maturity onset diabetes.

  1977cited by this paper
• Circulating proinsulin-like component in man: Increased proportion in hypoinsulinemic states

  1974cited by this paper
• Direct measurement of plasma proinsulin in normal and diabetic subjects.

  1972cited by this paper
• Immunoassay of Insulin: Two Antibody System: Plasma Insulin Levels of Normal, Subdiabetic and Diabetic Rats

  1963cited by this paper

• The impact of antidiabetic medications on COVID-19 outcomes in diabetic patients: an overview

  2024cites this paper
• Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future

  2018cites this paper
• Validated reversed phase HPLC method for determination of pioglitazone hydrochloride in bulk drug and tablet formulations

  2015cites this paper
• Acute exposure of beta-cells to troglitazone decreases insulin hypersecretion via activating AMPK.

  2014cites this paper
• Effets directs et aigus de médicaments insulinosensibilisateurs sur la cellule bêtades îlots pancréatiques : de l’outil de recherche à l’identification de la décélération métabolique comme mode d’action

  2013cites this paper
• Thiazolidinediones in Type 2 Diabetes Mellitus

  2012cites this paper
• Metabolic and Additional Vascular Effects of Thiazolidinediones

  2012cites this paper
• Pioglitazone safe, so save.

  2012cites this paper
• The role of peroxisome proliferator‐activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus

  2010cites this paper
• Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose

  2009cites this paper
• Effect of rosiglitazone and ramipril on-cell function in people with impaired glucose tolerance ( IGT ) or impaired fasting glucose ( IFG ) : the DREAM Trial . Running title : Rosiglitazone , ramipril and-cell function

  2009influential citation
• Thiazolidinediones and the preservation of β‐cell function, cellular proliferation and apoptosis

  2008cites this paper
• Simultaneous High-performance Liquid Chromatographic Determination of Metformin Hydrochloride and Rosiglitazone Maleate in Pharmaceutical-dosage Form

  2008cites this paper
• Perfil de expressão de genes modulados pela Pioglitazona em ilhotas pancreáticas murídeas

  2008cites this paper
• Efeito da pioglitazona sobre a viabilidade funcional e o índice de apoptose de ilhotas pancreáticas murídeas em cultura

  2008cites this paper
• Pioglitazone attenuates fatty acid–induced oxidative stress and apoptosis in pancreatic β‐cells

  2008cites this paper
• Thiazolidinediones dans le diabète de type 2 Rôle du peroxisome proliferator-activated receptor ? (PPAR?)

  2008cites this paper
• Troglitazone acutely activates AMP-activated protein kinase and inhibits insulin secretion from beta cells.

  2007cites this paper
• {beta}-Cell Differentiation and Secretory Function in the db/db Mouse Model of Diabetes Chronic Hyperglycemia, Independent of Plasma Lipid Levels, Is Sufficient for the Loss of

  2007cites this paper
• Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin‐18 is an independent factor for the improvement of homeostasis model assessment‐beta in type 2 diabetes mellitus

  2007cites this paper
• PPAR-γ Ligands and Diabetic Nephropathy

  2006cites this paper
• Vasoreactivity, Inflammation and vascular effects of Thiazolidinediones in Insulin resistance

  2006cites this paper
• Effects of pioglitazone on beta-cell function in metabolic syndrome patients with impaired glucose tolerance.

  2006cites this paper
• Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.

  2005cites this paper
• Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide.

  2005cites this paper
• IRIS II Study: Intact Proinsulin Is Confirmed as a Highly Specific Indicator for Insulin Resistance in a Large Cross-Sectional Study Design

  2005cites this paper
• Potential Role of Oral Thiazolidinedione Therapy in Preserving β-Cell Function in Type 2 Diabetes Mellitus

  2005cites this paper
• PPAR-gamma agonisti nella terapia del diabete mellito e di altre malattie endocrino-metaboliche

  2005cites this paper
• Thiazolidinediones as PPAR Agonists

  2004cites this paper
• Role of Intact Proinsulin in Diagnosis and Treatment of Type 2 Diabetes Mellitus

  2004cites this paper
• Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta.

  2004cites this paper
• Expression and functional activity of PPARγ in pancreatic β cells

  2004cites this paper
• Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells.

  2004cites this paper
• Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes.

  2004cites this paper
• β‐Cell mass plasticity in type 2 diabetes

  2004cites this paper
• Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity*

  2004cites this paper
• Thiazolidinediones: A Review of Their Mechanisms of Insulin Sensitization, Therapeutic Potential, Clinical Efficacy, and Tolerability

  2004cites this paper
• Peroxisome proliferator-activated receptor gamma (PPARγ) ligands and their therapeutic utility

  2004cites this paper
• The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.

  2004cites this paper
• Effect of PPAR-γ Activation and Inhibition on Glucose-Stimulated Insulin Release in INS-1e Cells

  2004cites this paper
• Long‐term glycaemic control with pioglitazone in patients with type 2 diabetes

  2004cites this paper
• Expression and functional activity of PPAR c in pancreatic b cells 1

  2004cites this paper
• Pioglitazone and sodium salicylate protect human β-cells against apoptosis and impaired function induced by glucose and interleukin-1β

  2004cites this paper
• Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.

  2004cites this paper
• Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

  2003cites this paper
• Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients

  2003cites this paper
• Insulin-sparing effects of troglitazone in rat pancreatic islets.

  2003influential citation
• Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.

  2003cites this paper
• Pharmacological Agents That Directly Modulate Insulin Secretion

  2003cites this paper
• Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease.

  2003cites this paper
• Therapeutic significance of peroxisome proliferator-activated receptor modulators in diabetes.

  2003cites this paper
• The prevention of type 2 diabetes--lifestyle change or pharmacotherapy? A challenge for the 21st century.

  2003cites this paper
• Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

  2003cites this paper
• Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation.

  2003cites this paper
• The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.

  2003cites this paper
• Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/dbmice

  2003cites this paper
• Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.

  2002cites this paper
• Comparison of metformin and thiazolidinediones in the management of polycystic ovary syndrome

  2002cites this paper
• Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus.

  2002cites this paper
• Effects of the Thiazolidinediones on Cardiovascular Risk Factors

  2002cites this paper
• Effects of thiazolidinediones on cardiovascular risk factors

  2002cites this paper
• Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.

  2002cites this paper
• Troglitazone does not protect rat pancreatic beta cells against free fatty acid-induced cytotoxicity.

  2002cites this paper
• Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.

  2002cites this paper
• [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].

  2002cites this paper
• Troglitazone ameliorates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma.

  2002cites this paper
• Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.

  2002cites this paper
• Thiazolidinediones for the prevention of diabetes in the non‐obese diabetic (NOD) mouse: implications for human type 1 diabetes

  2002cites this paper
• The evolution of β‐cell dysfunction and insulin resistance in type 2 diabetes

  2002cites this paper
• Thiazolidinediones: A Review of Their Benefits and Risks

  2002cites this paper
• Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.

  2002cites this paper
• Clinical evidence of thiazolidinedione‐induced improvement of pancreatic β‐cell function in patients with type 2 diabetes mellitus

  2002cites this paper
• New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.

  2001cites this paper
• Effects of high-dose troglitaz one on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits.

  2001cites this paper
• Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention.

  2001cites this paper
• Nonhypoglycemic Effects of Thiazolidinediones

  2001cites this paper
• Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.

  2001cites this paper
• Effects of high-dose troglitazone on insulin sensitivity and β-cell function in watanabe heritable hyperlipidemic rabbits

  2001influential citation
• Non Insulin-Dependent Diabetes Mellitus (Type 2) Secondary Failure. Metformin-Glibenclamide Treatment

  2001cites this paper
• The clinical effectiveness and cost effectiveness of rosiglitazone for type 2 diabetes mellitus: assessment report. NICE Technology Appraisal (TA9)

  2000cites this paper
• Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells.

  2000cites this paper
• The PPARs: from orphan receptors to drug discovery.

  2000cites this paper
• Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.

  2000cites this paper
• Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients.

  2000cites this paper
• The glitazones: proceed with caution.

  2000cites this paper
• [Insulin resistance: therapeutic approaches].

  1999cites this paper
• Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and inos expression.

  1999cites this paper
• A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.

  1999cites this paper
• Effect of troglitazone on the proinsulin level in patients with type 2 diabetes mellitus : A pilot study

  1999cites this paper
• Editorial: C-PEPTIDE PROFILING AND TYPE 2 DIABETES TREATMENT DECISIONS

  1999cites this paper
• Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?

  1999cites this paper
• In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression.

  1999cites this paper
• Troglitazone: a review of its use in the management of type 2 diabetes mellitus.

  1999cites this paper
• New strategies for the treatment of type 2 diabetes.

  1999cites this paper
• Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.

  1999cites this paper
• N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.

  1998cites this paper
• New therapeutic approaches to reversing insulin resistance.

  1998cites this paper
• Review Article Peroxisome Proliferator-activated Receptors in Diabetic Nephropathy

  year unknowncites this paper